Controversies in the management of early endometrial carcinoma: an update


  • P. Reddi Rani Department of Obstetrics and Gynecology, Mahatma Gandhi Medical College and Research Institute, Pilliarkuppam, Puducherry, India
  • Jasmina Begum Department of Obstetrics and Gynecology, Mahatma Gandhi Medical College and Research Institute, Pilliarkuppam, Puducherry, India
  • K. Sathyanarayana Reddy Department of Radiation Oncology, Mahatma Gandhi Medical College and Research Institute, Pilliarkuppam, Puducherry, India



Adjuvant treatment, Endometrial carcinoma, Lymphadenectomy


Endometrial carcinoma (EC) is the commonest genital tract malignancy in developing countries and is usually confined to the uterus at the time of diagnosis with excellent prognosis and high cure rates. But the management is associated with lot of controversies like in staging, best surgical approach, extent of lymphadenectomy, adjuvant therapy, fertility sparing surgery in young women etc. A thorough surgical staging is important to determine uterine and extrauterine spread and also understanding of the pathophysiology and management strategies to identify women who are at high risk and tailoring the adjuvant treatment if necessary without increasing the morbidity. This evidence based narrative review conducted by searching Medline (1994- 2015) and other online articles from Pubmed, Google scholar. Articles were selected based on their currency and relevance to the discussion they summarize the current literature to provide an approach to best practice management of early endometrial carcinoma.


Zhang Y, Wang J. Controversies in the management of endometrial carcinoma. Obstet Gynecol Int. 2010.

Gallup DG, Stock RJ. Adenocarcinoma of the endometrium in women 40 years of age or younger. Obstet Gynecol. 1984;64(3):417-20.

Colombo N, Preti E, Landoni F, Carinellis S. Endometrial cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow up. Ann Oncol. 2011;24(6):33-8.

Fader AN, Boruta D, Olawaiye AB. Uterine papillary serous carcinoma: epidemiology, pathogenesis and management. Curr Opin Obstet Gynecol. 2010:22(1):21-9.

Bansel N, Yendluri V, Wenhan RN. The molecular biology of endometrial cancers and the implications for pathogenesis, classification and targeted therapies. Cancer control. 2009:16(1):8-13.

Mutch DG. The new FIGO staging system for cancers of the vulva, cervix, endometrium and sarcomas. Gynecol Oncol. 2009:115;325-8.

Page BR, Pappas L, Cooke EW, Guffiny DK. Does the FIGO 2009 endometrial cancer staging system more accurately correlate with clinical outcome in different histologies? revised staging, endometrial cancer, histology. Int J Gynecol Cancer. 2012:22(4): 593-8.

Maggi G, Savino L, Susini T. Vaginal hysterectomy versus Abdominal Hystrectomy for treatment of Stage I endometrial adenocarcinoma. Am J Obstet Gynecol. 1996;174(4):1320-6.

Milan MR, Java J, Walker IL. Nodal metastasis risk in endometrioid endometrial carcinoma. Obstet Gynecol. 2012;119:286-92.

Creasman WT, Marrow CP, Bundy BM. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology group study. Cancer. 1987; 60(8):2035-41.

May K, Bryant A, Dickinson HO. Lymphadenectomy for the management of endometrial cancer (Review). The Cochrane database Syst Rev. 2010;20(1):7585.

Lutman CV, Havrilesky LJ, Cragun JM. “Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology,” Gynecologic Oncology. 2006; 102(1):92-7.

Chan JK, Cheung MK, Huh WK. “Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients. Cancer. 2006;107 (8):1823-30.

Nomura H, Aoki D, Suzuki N. “Analysis of clinicopathologic factors predicting para-aortic lymph node metastasis in endometrial cancer,” International Journal of Gynecological Cancer. 2006; 16(2):799-804.

Androutsopoulos G, Kotsopoulos IC, Decavalas G. The Role of Lymphadenectomy in Patients with Endometrial Cancer. J Gynecol Women’s Health. 2016;1(5):555573.

Christopher G, Saskatoom SK, Tien Le. The Role of surgery in endometrial carcinoma. Joint SOGC-GOC-SCC, clinical practical guideline. J Obstet Gynaecol Can. 2013;35(4A):S1-S8.

Walker JL, Piedmonte MR, Spirtos NM. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer. Gynecologic Oncology Group Study LAP2. J Clin Oncol. 2009;27(32):5331-6.

Gehreg PA, Cantrell LA, Shafer A. What is the optimal minimally invasive surgical procedure for endometrial cancer staging in obese and morbidity obese women? Gynecol Oncol. 2008;111(1):41-5.

Lee TS, Kim JW, Kim TJ, Cho CH, Ryu SY, Ryu HS, et al. Ovarian preservation during the surgical treatment of early stage endometrial cancer: a nation-wide study conducted by the Korean Gynecologic Oncology Group. Gynecol Oncol. 2009;115(1):26-31.

Walsh C, Holschneider C, Hoang Y, Tieu K, Karlan B, Cass I. Coexisting ovarian malignancy in young women with endometrial cancer. Obstet Gynecol. 2005;106(4):693-9.

William MB, James Orr, Mario L, Emery S et al. Endometrial cancer: A review and current management strategies: Part II. Gynecologic Oncology. 2014;134:393-402.

Erkanli S, Ayhan A. Fertility-sparing therapy in young womenwith endometrial cancer:2010 update. Int J Gynecol Cancer. 2010;20(7):1170-87.

Wright JD. Management of endometrial cancer in young women Clin Obstet Gynecol. 2011;54(2):219-25.

Colombo N, Creutzberg C, Amant F. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Int J Gynecol Cancer. 2016;26:2-30.

Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Warlam-Rodenhuis CC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial PORTEC Study Group. Post-operative radiation therapy in endometrial carcinoma. Lancet. 2000;355(9213): 1404-11.

Nout RA, Van de Poll - Frange LV, Lybert M. Long term outcome and quality of life of patients with endometrial carcinoma treated with or without pelvic radiotherapy in the postoperative radiation therapy in endometrial carcinoma 1 (PORTEC -1) trial. J Clin Oncol. 2011;29(13):1692-700.

Nout RA, Putter H, Jurgenliemk-Schuliz IM. Five-year quality of life of endometrial cancer patients treated in randomized post-operative radiation therapy in endometrial cancer (PORTEC -2) trail and comparison with normal data. Eur J Cancer. 2012; 48(11);1638-48.

Maggi R, Lissoni A, Spina F. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: Results of a randomised trial. Br J Cancer. 2006;95:266-71.

Susumu N, Sagae S, Udagawa Y. Randomized phase III trial of pelvic radiotherapy versus cisplatin-basedcombinedchemotherapy in patients with intermediate- and high-risk endometrial cancer: A Japanese Gynecologic Oncology Group study. Gynecol Oncol. 2008;108:226-33.

Kupets R, Le T, Bentley J. The role of adjuvant therapy in endometrial cancer. J Obstet Gynaecol Can. 2013;35(4B):S1-S9.

Mueck AO, Seeger H. Hormone therapy after endometrial cancer. Endocr Relat Cancer 2004;11(2): 305-14.

National Comprehensive Cancer Network. (NCCN) Clinical Practical Guidelines in oncology. (NCCN Guidelines TM) Uterine neoplasms version 1. Fort Washington PA: NCCN; 2010.

Grammatoglou X, Skafida E, Glava C, Katsamagkou E, Delliou E, Vasilakaki T. Synchronous endometrioid carcinoma of the uterine corpus and ovary. A case report and review of the literature. Eur J Gynaecol Oncol. 2009;30(4):437-9.

American Cancer Society. Cancer Facts and Figures 2016. Atlanta: American cancer society; 2016.

Greer BE, Koh WJ, Abu-Rustum N, Bookman MA, Bristow RE, Campos SM, et al. Uterine neoplasms. Clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2009;7(5):498-531.






Review Articles